# Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

> **NCT00375752** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 168 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Zolendronic Acid

## Key facts

- **NCT ID:** NCT00375752
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06-01
- **Primary completion:** 2010-12-16
- **Final completion:** 2010-12-16
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375752, "Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00375752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*